Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Sm… (NCT00062205) | Clinical Trial Compass
CompletedPhase 2
Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor
United States40 participantsStarted 2002-06
Plain-language summary
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.
PURPOSE: This phase II trial is studying how well imatinib mesylate works in treating patients with recurrent Ewing's family of tumors or desmoplastic small round-cell tumor.
Who can participate
Age range16 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DISEASE CHARACTERISTICS:
* Diagnosis of Ewing's family of tumors OR desmoplastic small round-cell tumor
* Must have immunohistochemical evidence of expression of greater than 2+/4+ for either Kit (CD117) or platelet-derived growth factor receptor -a or -b
* No symptomatic brain metastases
* Asymptomatic brain metastases are allowed provided patient is not on concurrent anticonvulsants or corticosteroids
PATIENT CHARACTERISTICS:
Age
* Over 16
Performance status
* ECOG 0-2
Life expectancy
* Not specified
Hematopoietic
* Absolute neutrophil count greater than 1,500/mm\^3
* Platelet count greater than 100,000/mm\^3
* Hemoglobin greater than 9 g/dL
Hepatic
* Bilirubin less than 1.5 times upper limit of normal (ULN)
* SGOT and SGPT less than 2.5 times ULN
* No chronic active hepatitis
* No cirrhosis
* No other acute or known chronic liver disease
Renal
* Creatinine less than 1.5 times ULN
Cardiovascular
* No concurrent poorly controlled or severe cardiovascular disease
Pulmonary
* No concurrent poorly controlled or severe pulmonary disease
Other
* HIV negative
* No concurrent poorly controlled or severe central nervous system disease
* No other concurrent poorly controlled or severe nonmalignant disease
PRIOR CONCURRENT THERAPY:
Biologic therapy
* Not specified
Chemotherapy
* At least 3 weeks since prior chemotherapy
Endocrine therapy
* See Disease Characteristics
Radiotherapy
* At least 3 weeks since prior radiotherapy
Surgery
* More than 2 weeks …